A recent experiment found that a new obesity therapy medicine called Wegovy greatly lowered the risk of cardiac issues in those who were overweight or obese, even if they did not have diabetes. In adults with pre-existing heart disease, the medicine semaglutide lowered the risk of major cardiovascular events such as heart attacks and strokes by 20%. This is the first time that an obesity medicine has been demonstrated to protect against cardiovascular disease in people who do not have diabetes. According to experts, if the findings are validated, it might transform how these new obesity medicines are administered and utilized in preventive cardiology. Researchers were blown away by the dramatic impact on health that went beyond weight reduction, comparing it to statins in terms of the benefits it revealed for heart health. According to the data, these novel obesity medicines may be effective.

To know more: About the original article click here.